Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.87
BGMD's Cash to Debt is ranked lower than
69% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.71 vs. BGMD: 0.87 )
Ranked among companies with meaningful Cash to Debt only.
BGMD' s 10-Year Cash to Debt Range
Min: 0.68  Med: 5.52 Max: No Debt
Current: 0.87
Equity to Asset -0.22
BGMD's Equity to Asset is ranked lower than
96% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. BGMD: -0.22 )
Ranked among companies with meaningful Equity to Asset only.
BGMD' s 10-Year Equity to Asset Range
Min: -12.54  Med: 0.05 Max: 0.88
Current: -0.22
-12.54
0.88
F-Score: 3
Z-Score: -91.70
M-Score: -3.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -268.45
BGMD's Operating margin (%) is ranked lower than
84% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. BGMD: -268.45 )
Ranked among companies with meaningful Operating margin (%) only.
BGMD' s 10-Year Operating margin (%) Range
Min: -1783.39  Med: -345.92 Max: -69.34
Current: -268.45
-1783.39
-69.34
Net-margin (%) -291.11
BGMD's Net-margin (%) is ranked lower than
84% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.80 vs. BGMD: -291.11 )
Ranked among companies with meaningful Net-margin (%) only.
BGMD' s 10-Year Net-margin (%) Range
Min: -2095.48  Med: -339.23 Max: -78.43
Current: -291.11
-2095.48
-78.43
ROE (%) -1392.22
BGMD's ROE (%) is ranked lower than
99% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.85 vs. BGMD: -1392.22 )
Ranked among companies with meaningful ROE (%) only.
BGMD' s 10-Year ROE (%) Range
Min: -224.23  Med: -224.23 Max: -224.23
Current: -1392.22
ROA (%) -110.27
BGMD's ROA (%) is ranked lower than
91% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.53 vs. BGMD: -110.27 )
Ranked among companies with meaningful ROA (%) only.
BGMD' s 10-Year ROA (%) Range
Min: -174.66  Med: -110.60 Max: -67.46
Current: -110.27
-174.66
-67.46
ROC (Joel Greenblatt) (%) -4873.17
BGMD's ROC (Joel Greenblatt) (%) is ranked lower than
95% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.66 vs. BGMD: -4873.17 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BGMD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -9110.84  Med: -1810.96 Max: -327.37
Current: -4873.17
-9110.84
-327.37
EBITDA Growth (3Y)(%) -39.00
BGMD's EBITDA Growth (3Y)(%) is ranked lower than
87% of the 102 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. BGMD: -39.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BGMD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: 0.00 Max: -39
Current: -39
EPS Growth (3Y)(%) -37.00
BGMD's EPS Growth (3Y)(%) is ranked lower than
81% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. BGMD: -37.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BGMD' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: 0.00 Max: -37
Current: -37
» BGMD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

BGMD Guru Trades in Q1 2014

Paul Tudor Jones 11,879 sh (-57.03%)
» More
Q2 2014

BGMD Guru Trades in Q2 2014

Paul Tudor Jones 11,879 sh (unchged)
» More
Q3 2014

BGMD Guru Trades in Q3 2014

Paul Tudor Jones 11,779 sh (-0.84%)
» More
Q4 2014

BGMD Guru Trades in Q4 2014

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BGMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 7.60
BGMD's P/S is ranked lower than
78% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.93 vs. BGMD: 7.60 )
Ranked among companies with meaningful P/S only.
BGMD' s 10-Year P/S Range
Min: 3.33  Med: 11.83 Max: 121
Current: 7.6
3.33
121
Current Ratio 0.74
BGMD's Current Ratio is ranked lower than
94% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. BGMD: 0.74 )
Ranked among companies with meaningful Current Ratio only.
BGMD' s 10-Year Current Ratio Range
Min: 0.3  Med: 1.46 Max: 7.97
Current: 0.74
0.3
7.97
Quick Ratio 0.65
BGMD's Quick Ratio is ranked lower than
92% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.39 vs. BGMD: 0.65 )
Ranked among companies with meaningful Quick Ratio only.
BGMD' s 10-Year Quick Ratio Range
Min: 0.3  Med: 1.41 Max: 7.96
Current: 0.65
0.3
7.96
Days Inventory 167.58
BGMD's Days Inventory is ranked lower than
84% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.61 vs. BGMD: 167.58 )
Ranked among companies with meaningful Days Inventory only.
BGMD' s 10-Year Days Inventory Range
Min: 62.5  Med: 122.36 Max: 163.98
Current: 167.58
62.5
163.98
Days Sales Outstanding 19.39
BGMD's Days Sales Outstanding is ranked higher than
95% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.73 vs. BGMD: 19.39 )
Ranked among companies with meaningful Days Sales Outstanding only.
BGMD' s 10-Year Days Sales Outstanding Range
Min: 11.95  Med: 46.78 Max: 350.29
Current: 19.39
11.95
350.29

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.66
BGMD's Price/Median PS Value is ranked higher than
79% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. BGMD: 0.66 )
Ranked among companies with meaningful Price/Median PS Value only.
BGMD' s 10-Year Price/Median PS Value Range
Min: 0.42  Med: 1.10 Max: 9.89
Current: 0.66
0.42
9.89
Earnings Yield (Greenblatt) (%) -33.36
BGMD's Earnings Yield (Greenblatt) (%) is ranked lower than
87% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. BGMD: -33.36 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BGMD' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -37.3  Med: 0.00 Max: 0
Current: -33.36
-37.3
0

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:RBM.Germany,
BG Medicine is a life sciences company engaged into discovery, development, and commercialization of novel diagnostic tests based on biomarkers. Its tests include BGM Galectin-3, CardioSCORE.
» More Articles for BGMD

Headlines

Articles On GuruFocus.com
comment on BGMD Jun 09 2011 

More From Other Websites
BG MEDICINE, INC. Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Creation of a... Jun 09 2015
BG MEDICINE, INC. Financials May 27 2015
10-Q for BG Medicine, Inc. May 17 2015
BG MEDICINE, INC. Files SEC form 10-Q, Quarterly Report May 15 2015
BG Medicine Reports First Quarter 2015 Financial Results May 14 2015
BG MEDICINE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events,... May 14 2015
BG Medicine Reports First Quarter 2015 Financial Results May 14 2015
Q1 2015 BG Medicine Inc Earnings Release - Before Market Open May 14 2015
BG MEDICINE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a... May 12 2015
BG Medicine Announces Q1 2015 Financial Results Release Date and Conference Call Information May 07 2015
BG Medicine Announces Q1 2015 Financial Results Release Date and Conference Call Information May 07 2015
Nasdaq stocks posting largest volume increases Apr 29 2015
Most active Nasdaq-traded stocks Apr 29 2015
10-K for BG Medicine, Inc. Apr 25 2015
BG MEDICINE, INC. Files SEC form 8-K, Change in Directors or Principal Officers Apr 15 2015
BG Medicine Submits 510(k) to FDA for Additional Indication for the BGM Galectin-3(R) Test Mar 31 2015
BG Medicine Reports 2014 Fourth Quarter and Year End Financial Results Mar 31 2015
BG MEDICINE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events,... Mar 31 2015
BG Medicine Welcomes Major Publication on the BioImage Study in the Journal of the American College... Mar 26 2015
BG Medicine Announces Fiscal Year 2014 Financial Results Release Date and Conference Call... Mar 24 2015
BG Medicine Announces Receipt of NASDAQ Notice of Non-Compliance; Intends to Request Hearing and... Mar 13 2015
BG MEDICINE, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing... Mar 13 2015
BG Medicine Announces Receipt of Favorable NASDAQ Listing Determination Feb 02 2015
PAREXEL International Q2 Earnings, Revenues Top Estimates - Analyst Blog Jan 29 2015
Zacks Rank #1 Additions for Wednesday - Tale of the Tape Jan 21 2015
BG MEDICINE, INC. Files SEC form 8-K, Other Events Dec 30 2014
BG MEDICINE, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing... Nov 26 2014
BG Medicine, Inc. Welcomes Presentation of Clinical Data on Galectin-3 Testing at the American Heart... Nov 21 2014
BG MEDICINE, INC. Files SEC form 10-Q, Quarterly Report Nov 14 2014
BG Medicine Reports Third Quarter 2014 Financial Results Nov 13 2014
BG MEDICINE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Nov 13 2014
BG Medicine Announces Q3 2014 Financial Results Release Date and Conference Call Information Nov 07 2014
BG MEDICINE, INC. Files SEC form 8-K, Other Events Oct 17 2014
BG MEDICINE, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Notice of... Sep 11 2014
BG MEDICINE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Aug 14 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK